Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito

Newsletter "Clinica dell'Alcolismo"

N. 48 (2016)

La terapia farmacologica dell'alcolismo: i farmaci anti-alcol non ancora autorizzati dagli organismi regolatori ma utilizzati nella pratica clinica o in fase di sperimentazione. I farmaci che modulano il sistema del glutammato: il topiramato e il gabapent

25 September 2017

Riferimenti bibliografici

  1. American Psychiatric Association (APA) (1994), DSM-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Washington DC: American Psychiatric Press.
  2. American Psychiatric Association (APA) (2000), DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, Washington DC: American Psychiatric Press.
  3. Anthenelli R.M., Blom T.J., McElroy S.L., Keck P.E.Jr. (2008), “Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation”, Addiction, 103, 687-694.
  4. Anton R.F., Moak D.H., Lathan P. (1995), “The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior”, Alcoholism: Clinical and Experimental Research, 19, 92-99.
  5. Anton R.F., Moak D.H., Lathan P. (1996), “The Obsessive Compulsive Drinking Scale: a new method of assessing outcome in alcoholism treatment studies”, Archives of General Psychiatry, 53, 225-231.
  6. Anton R.F., Dominick C., Bigelow M., Websty C. (2001), “CDTect Research Group: Comparison of Bio-Rad%CDT TIA and CDTTect as laboratory markers of heavy alcohol use and their relationship with γ-glutamyltransferase”, Clinical Chemistry, 47, 1769-1775.
  7. Anton R.F., O’Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A., for the COMBINE Study Research Group (2006), “Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial”, JAMA, 295, 2003-2017.
  8. Anton R.F., Myrick H., Baros A.M., Latham P.K., Randall P.K., Wright T.M., Stewart S.H., Waid R., Malcolm R (2009), “Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms”, Journal of Clinical Psychopharmacology, 29, 334-342.
  9. Anton R.F., Myrick H., Wright T.M., Latham P.K., Baros A.M., Waid L.R., Randall P.K. (2011), “Gabapentin combined with naltrexone for the treatment of alcohol dependence”, American Journal of Psychiatry, 168, 709-717.
  10. Appolinario J.C., Fontenelle L.F., Papelbaum M., Bueno J.R., Coutinho W. (2002), “Topiramate use in obese patients with binge eating disorder: an open study”, Canadian Journal of Psychiatry, 47, 271-273.
  11. Arbaizar B., Gómez-Acebo I., Llorca J. (2008), “Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a sysstematic review”, General Hospital Psychiatry, 30, 471-475.
  12. Arbaizar B., Diersen-Sotos T., Gómez-Acebo I., Llorca J. (2010), “Topiramate in the treatment of alcohol dependence: a metaanalysis”, Actas Españolas de Psiquiatría, 38, 8-12.
  13. Banger M., Philipp M., Herth T., Hebenstreit M., Aldenhoff J.B. (1992), “Development of a rating scale for quantitative measurement of the alcohol withdrawal syndrome”, European Archives of Psychiatry and Clinical Neuroscience, 241, 241-246.
  14. Bastien C.H., Vallières A., Morin C.M. (2001), “Validation of the Insomnia Severity Index as an outcome measure for insomnia research”, Sleep Medicine, 2, 297-307.
  15. Batki S.L., Pennington D.L., Lasher B., Neylan T.C., Metzler T., Waldrop A., Delucchi K., Herbst E. (2014), “Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial”, Alcoholism: Clinical and Experimental Research, 38, 2169-2177.
  16. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. (1961), “An inventory for measuring depression”, Archives of General Psychiatry, 4, 561-571.
  17. Beck A.T., Epstein N., Brown G., Steer R.A. (1988), “An inventory for measuring clinical anxiety: psychomatric properties”, Journal of Consulting and Clinical Psychology, 56, 893-897.
  18. Beck A.T., Steer R.A., Ball R., Ranieri W. (1996), “Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients”, Journal of Personality Assessment, 67, 588-597.
  19. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., Pallanti S., Hollander E. (2011), “Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessivecomplulsive disorder”, Journal of Clinical Psychiatry, 72, 716-721.
  20. Berlin H.A., Braun A., Simeon D., Koran L.M., Potenza M.N., McElroy S.L., Fong T., Pallanti S., Hollander E. (2013), “A double-blind, placebo-controlled trial of topiramate for pathological gamblingr”, World Journal of Biological Psychiatry, 14, 121-128.
  21. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., Gusman F.D., Charney D.S., Keane T.M. (1995), “The development of a Clinician-Administerd PTSD Scale”, Journal of Traumatic Stress, 8, 75-90.
  22. Blodgett J.C., Del Re A.C., Maisel N.C., Finney J.W. (2014), “A metaanalysis of topiramate’s effects for individuals with alcohol use disorders”, Alcoholism: Clinical and Experimental Research, 38, 1481-1488.
  23. Bohn M.J., Krahn D.D., Staehler B.A. (1995), “Development and initial validation of a measure of drinking urges in abstinent alcoholics”, Alcoholism: Clinical and Experimental Research, 19, 600-606.
  24. Bonnet U., Banger M., Leweke F.M., Specka M., Müller B.W., Hashemi T., Nyhuis P.W., Kutscher S., Burtscheidt W., Gastpar M. (2003), “Treatment of acute alcohol withdrawal with gabapentin: Results from a controlled two-center trial”, Journal of Clinical Psychopharmacology, 23, 514-519.
  25. Bonnet U., Hamzavi-Abedi R., Specka M., Wiltfang J., Lieb B., Scherbaum N. (2010), “An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol“, Alcohol and Alcoholism, 45, 143-145.
  26. Book S.W., Myrick H. (2005), “Novel anticonvulsants in the treatment of alcoholism”, Expert Opinion on Investigational Drugs, 14, 371-376.
  27. Bradley M.M., Lang P.J. (1994), “Measuring emotion: the self-assessment manikin and the semantic differential”, Journal of Behavior Therapy and Experimental Psychiatry, 25, 49-59.
  28. Brandt J. (1991), “The hopkins verbal learning test: development of a new memory test with six equivalent forms”, Clinical Neuropsychologist, 5, 125-142.
  29. Buysse D.J., Reynolds C.F. 3rd, Monk T.H., Berman S.R., Kupfer D.J. (1989), “The Pittsburg Sleep Quality Index: a new instrument for psychiatric practice and research”, Psychiatry Research, 28, 193-213.
  30. Conners C.K. (2000), Conners’ Continuous Performance Test-II, Toronto: Multi-Health Systems.
  31. Dannon P.N., Lowengrub K., Musin E., Gonopolsky Y., Kotler M. (2007), “12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study”, Journal of Clinical Psychopharmacology, 27, 620-624.
  32. Derogatis L R. (1983), SCL-90-R: Administration, Scoring, and Procedures Manual II, Baltimore: Clinical Psychometric Research.
  33. Derogatis L.R. (1994), Symptom Checklist 90-R: Administration, Scoring, and Procedures Manual (3rd ed.), Minneapolis: National Computer Systems.
  34. Falk D.E., Wang X.Q., Liu L., Fertig J., Mattson M., Ryan M., Johnson B.A., Stout R., Litten R.Z. (2010), “Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials”, Alcoholism: Clinical and Experimental Research, 34, 2022-2034.
  35. First M.B., Spitzer R.L., Gibbon M.G., Williams J.B.W. (1996), Structured Clinical Interview for DSM-IV-Axis I Disorders-Patient Edition (SCID-IP, Version 2.0), New York: Biometrics Research Department, New York State Psychiatric Institute.
  36. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. (1997), Structured Clinical Interview for DSM IV Axis I Disorders (SCID I) Clinical Version, Washington DC: American Psychiatric Publishing.
  37. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. (2001), Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/PW/PSY Screen), New York: Biometric Research, New York State Psychiatric Institute.
  38. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. (2002), Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I-P), Research Version, Patient Edition, New York: Biometrics Research, New York State Psychiatric Institute.
  39. Flannery B.A., Volpicelli J., Pettinati H.M. (1999), “Psychometric properties of the Penn Alcohol Craving Scale”, Alcoholism: Clinical and Experimental Research, 23, 1289-1295.
  40. Flòrez G., Saiz PA, García-Portilla P., Alvarez S., Nogueiras L., Bobes J. (2011), “Topiramate for the treatment of alcohol dependence: comparison with naltrexone”, European Addiction Research, 17, 29-36.
  41. Folstein M.F., Folstein S.E., McHugh P.R. (1975) “Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician”, Journal of Psychiatric Research,12, 189-198.
  42. Fromme K., Stroot E.A., Kaplan D. (1993), “Comprehensive effects of alcohol: Development and psychometric assessment of a new expectancy questionnaire”, Psychological Assessment, 5, 19-26.
  43. González G., Desai R., Sofuoglu M., Poling J., Oliveto A., Gonsai K., Kosten T.R. (2007), “Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients”, Drug and Alcohol Dependence, 87, 1-9.
  44. Gormally J., Black S., Daston S., Rardin D. (1982), “The assessment of binge eating severity among obese persons”, Addictive Behaviors, 7, 47-55.
  45. Guglielmo R., Martinotti G., Quatrale M., Ioime L., Kadilli I., Di Nicola M., Janiri L. (2015), “Topiramate in alcohol use disorders: review and update”, CNS Drugs, 29, 383-395.
  46. Gutiérrez García M.L., Blasco-Algora S., Fernández-Rodríguez C.M. (2015), “Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence”, World Journal of Gastroenterology, 21, 8516-8526.
  47. Guy W. (1976), Clinical Global Impressions in ECDEU Assessment Manual for Psycopharmacology, Rockville: Psycopharmacology Research Branch, National Institute of Health, 217-222.
  48. Haass-Koffler C.L., Leggio L., Kenna G.A. (2015), “Pharmacological approaches to reducing craving in patients with alcohol use disorders”, CNS Drugs, 28, 343-360.
  49. Halikas J.A., Kuhn K.L., Crosby R., Carlson C., Crea F. (1991), “The measurement of craving in cocaine patients using the Minnesota Cocaine Craving Scale”, Comprehensive Psychiatry, 32, 22-27.
  50. Handelsman L., Cochrane K.J., Aronson M.J., Ness R., Rubinstein K.J., Kanof P.D. (1987), “Two New Rating Scales for Opiate Withdrawal”, American Journal of Drug and Alcohol Abuse, 13, 293-308.
  51. Hayes M.H.S., Patterson D.G. (1921), “Experimental development of the graphic rating scale”, Psychology Bulletin, 18, 98-99.
  52. Heinzerling K.G., Shoptaw S., Peck J.A., Yang X., Liu J., Roll J., Ling W. (2006), “Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence”, Drug and Alcohol Dependence”, 85, 177-184.
  53. Hoopes S.P., Reimherr F.W., Hedges D.W., Rosenthal N.R., Kamin M., Capece J.A., Karvois D. (2003), “Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures”, Journal of Clinical Psychiatry, 64, 1335-1341.
  54. Johns M.W. (1991), “A new method for measuring daytime sleepiness: the
  55. Epworth Sleepiness Scale”, Sleep, 14, 540-545.
  56. Johnson B.A. (2004), “Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study”, Alcoholism: Clinical and Experimental Research, 28, 1137-1144.
  57. Johnson B.A., Ait-Daout N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., Javors M.A., Ma J.Z. (2003a), “Oral topiramate for treatment of alcohol dependence: a randomised controlled trial”, Lancet, 361, 1677-1685.
  58. Johnson B.A., DiClemente C.C., Ait-Daout N., Stoks S.M. (2003b) “Brief Behavioral Compliance Enhancement Treatment (BBCET) manual”, in Handbook of clinical alcoholism treatment, editors: Johnson B.A., Ruiz P., Galanter M. Baltimore: Lippincott Williams & Wilkins, 282-301.
  59. Johnson B.A., Ait-Daout N, Akhtar F.Z., Ma J.Z. (2004), “Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial”, Archives of General Psychiatry, 61, 905-912.
  60. Johnson B.A., Ait-Daoud N., Akhtar F.Z., Javors M.A. (2005), “Use of oral topiramate to promote smoking abstinence among alcoholdependent smokers: a randomized controlled trial”, Archives of Internal Medicine, 165, 1600-1605.
  61. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O’Malley S.S., Swift R.M.; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group (2007), “Topiramate for treating alcohol dependence: a randomized controlled trial”, JAMA, 298, 1641-1651.
  62. Johnson B.A., Rosenthal N., Capace J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Addolorato G., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O’Malley S.S., Swift R.M.; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group (2008), “Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial”, Archives of Internal Medicine, 168, 1188-1199.
  63. Jonas D.E., Amick H.R., Feltner C., Bobashev G., Thomas K., Wines R., Kim M.M., Shanahan E., Gass C.E., Rowe C.J., Garbutt J.C. (2014), “Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings [Internet]”, AHRQ Agency for Healthcare Research and Quality-Rockville, Comparative Effectiveness Review, Report No. 134: 14-EHC029-EF, 1-447.
  64. Kadden R., Carroll K.M., Donovan D., Cooney N., Monti P., Abrams D., Litt M., Hester R. (1992), Cognitive Behavioral Coping Skills Manual, Washintgon DC: U.S. Governmment Printing Office.
  65. Kampman K.M., Volpicelli J.R., McGinnis D.E., Alterman A.I., Weinieb R.M., D’Angelo L.D., Epperson L. (1998), “Reliability and validity of the cocaine selective severity assessment”, Addictive Behaviors, 23, 449-461.
  66. Kampman K.M., Pettinati H.M., Lynch K.G., Spratt K., Wierzbicki M.R., O’Brien C.P. (2013), “A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence”, Drug and Alcohol Dependence, 133, 94-99.
  67. Khazaal Y., Zullino D.F. (2006), “Topiramate in the treatment of compulsive sexual behavior: care report”, BMC Psychiatry, 6, 22.
  68. Kheirabadi G.R., Ranjkesh M., Maracy M.R., Salehi M. (2008), “Effect of add-on gabapentin on opioid withdrawal symptoms in opiumdependent patients”, Addiction, 103, 1495-1499.
  69. Kenna G.A., Lomastro T.L., Schiesl A., Leggio L., Swift R.M. (2009), “Review of topiramate: an antiepileptic for the treatment of alcohol dependance”, Current Drug Abuse Reviews, 2, 135-142.
  70. Kokkevi A., Hartgers C. (1995), “EuropAsi: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence”, European Addiction Research, 1, 208-210.
  71. Kranzler H.R., Gelernter J., Anton R.F., Arias A.J., Herman A., Zhao H., Burian L., Covault J. (2009), “Association of markers in the 3’ region of the GluR5 kainate receptor subunit gene to alcohol dependence”, Alcoholism: Clinical and Experimental Research, 33, 925-930.
  72. Kranzler H.R., Covault J., Feinn R., Armeli S., Tennen H., Arias A.J., Gelernter J., Pond T., Oncken C., Kampman K.M. (2014a), “Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism”, American Journal of Psychiatry, 171, 445-452.
  73. Kranzler H.R., Armeli S., Feinn R., Tennen H., Gelernter J., Covault J. (2014b), “GRIK1 genotype moderates topiramate’s effects on dealy drinking level, expectations of alcohol’s positive effects and desire to drink”, International Journal of Neuropsychopharmacology, 17, 1549-1556.
  74. Kranzler H.R., Feinn R., Gelernter J., Pond T., Covault J. (2014c), “Topiramate’s reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism”, Experimental and Clinical Psychopharmacology, 22, 419-423.
  75. Kranzler H.R., Wetherill R., Feinn R., Pond T., Gelernter J., Covault J. (2014d), “Posttreatment effects of topiramate treatment for heavy drinking”, Alcoholism: Clinical and Experimental Research, 38, 3017-3023.
  76. Kranzler H.R., Armeli S., Wetherill R., Feinn R., Tennen H., Gelernter J., Covault J., Pond T. (2016), “Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking”, Addiction Biology, 21, 450-459.
  77. Landmark C.J. (2007), “Targets for antiepileptic drugs in the synapse”, Medical Science Monitor, 13, RA1-RA7.
  78. Leigh B.C., Stacy A.W. (1993), “Alcohol outcome expectancies: Scale construction and predictive utility in higher order confirmatory models”, Psychological Assessment, 5, 216-229.
  79. Leung J.G., Hall-Flavin D., Nelson S., Schmidt K.A., Schak K.M. (2015), “The role of gabapentin in the management of alcohol withdrawal and dependence”, Annals of Pharmacotherapy, 49, 897-906.
  80. Levine J., Schooler N.R (1986), “SAFTEE: a technique for the systematic assessment of side effects in clinical trials”, Psychopharmacology Bulletin, 22, 343-381.
  81. Martin W.R., Sloan J.W., Sapira J.D., Jasinski D.R. (1971), “Physiologic, subjective and behavioral effects of amphetamine, ephedrine, phemetrazine, and methylphenidate in man”, Clinal Pharmacology and Therapeutics, 12, 245-258.
  82. Martinotti G., Di Nicola M., De Vita O., Hatzigiakoumis D.S., Guglielmo R., Santucci B., Aliotta F., Romanelli R., Verrastro V., Petruccelli F., Di Giannantonio M., Janiri L. (2014), “Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study”, Journal of Clinical Psychopharmacology, 34, 709-715.
  83. Mason B.J., Light J.M., Williams L.D., Drobes D.J. (2009), “Proof-of concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin”, Addiction Biology, 14, 73-83.
  84. Mason B.J., Quello S., Goodell V., Shadan F., Kyle M., Begovic A. (2014), “Gabapentin treatment for alcohol dependence: a randomized clinical trial”, JAMA Internal Medicine, 174, 70-77.
  85. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grisson G., Pettinati H., Argeriou M. (1992), “The fifth edition of the Addiction Severity Index”, Journal of Substance Abuse Treatment, 9, 199-213.
  86. McNair D.M., Lorr M., Droppleman L.F. (1971), Manual for the Profile of Mood States, San Diego: Educational & Industrial Testing Service.
  87. Mello M.F., Yeh M.S.L., Barbosa Neto J., Braga L.L., Fiks J.P., Mendes D.D., Moriyama T.S., Valente N.L., Costa M.C., Mattos P., Bressan R.A., Andreoli S.B., Mari J.J. (2009), “A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder”, BMC Psychiatry, 9, 1-7.
  88. Mersfelder T.L., Nicholas W.H. (2016), “Gabapentin: abuse, dependence, and withdrawal”, Annals of Pharmacotherapy, 50, 229-233.
  89. Miller W. R. (1996), Form 90: A structured assessment interview for drinking and related behaviors (Test Manual), NIAAA Project MATCH Monograph Series, National Institute of Health (NIH) Publication No. 96-4004, Bethesda: National Institute on Alcohol Abuse and Alcoholism.
  90. Miller W.R. (2004), Combined Behavioral Intervention Manual: A clinical research guide for therapists treating people with alcohol abuse and dependence, in DHHS Publication No. (NIH) 04-5288, editor: Mattson M.E., Bethesda: National Institute on Alcohol Abuse and Alcoholism.
  91. Miller W.R., Tonigan J.S., Longabaugh R. (1995), The Dinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse, NIAAA Project MATCH Monograph Series, Vol. 4, National Institute of Health (NIH) Publication No. 95-391, Bethesda: National Institute on Alcohol Abuse and Alcoholism.
  92. Miranda R.Jr., MacKillop J., Treloar H., Blanchard A., Tidey J.W., Swift R., Chun T., Rohsenow D.J., Monti P.M. (2016), “Biobehavioral mechanisms of topiramate’s effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments”, Addiction Biology, 21, 171-182.
  93. Montgomery S.A., Åsberg M. (1979), “A new depression scale designed to be sensitive to change”, British Journal of Psychiatry, 134, 328-389.
  94. Mottola C.A. (1993), “Measurement strategies: the visual analogue scale”, Decubitus, 6, 56-58.
  95. Mowla A., Kardeh E. (2011), “Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial”, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 970-973.
  96. Myrick H., Henderson S., Brady K.T., Malcolm R. (2001), “Gabapentin in the treatment of cocaine dependence: a case series”, Journal of Clinical Psychiatry, 62, 19-23.
  97. Myrick H., Malcolm R., Randall P.K., Boyle E., Anton R.F., Becker H.C., Randall C.L. (2009), “A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal”, Alcoholism: Clinical and Experimental Research, 33, 1582-1588.
  98. National Institute on Alcohol Abuse and Alcoholism-NIAAA (1995), The physicians’ guide to helping patients with alcohol problems, Rockville: U.S. Department of Health and Human Services.
  99. Nickel M.K., Nickel C., Mitterlehner F.O., Tritt K., Lahmann C., Leiberich P.K., Rother W.K., Loew T.H. (2004), “Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study”, Journal of Clinical Psychiatry, 65, 1515-1519.
  100. Nuijten M., Blanken P., van den Brink W., Hendriks V. (2014), “Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in The Netherlands”, Drug and Alcohol Dependence, 138, 177-184.
  101. Nunes E.V. (2014), “Gabapentin: A new addition to the armamentarium for alcohol dependence?”, JAMA Internal Medicine, 174, 78-79.
  102. Olive M.F., Cleva R.M., Kalivas P.W., Malcolm R.J. (2012), “Glutamatergic medications for the treatment of drug and behavioural addictions”, Pharmacology, Biochemistry, and Behavior, 100, 801-810.
  103. Olmsted C.L., Kockler D.R. (2008), “Topiramate for alcohol dependence”, Annals of Pharmacotherapy, 42, 1475-1480.
  104. Pettinati H.M., Weiss R.D., Dundon W., Miller W.R., Donovan D., Ernst D.B., Rounsaville B.J. (2005), “A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence”, Journal of Studies on Alcohol and Drugs, Suppl. 15, 170-178.
  105. Reis A.D., Castro L.A., Faria R., Laranjeira R. (2008), “Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial”, Revista Brasileira de Psiquiatria, 30, 132-135.
  106. Reitan R.M., Wolfson D. (1993), The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation, 2nd ed., Tucson: Neuropsychology Press.
  107. Roberts J.S., Anton R.F., Latham P.K., Moak D.H. (1999), “Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale”, Alcoholism: Clinical and Experimental Research, 23, 1484-1491.
  108. Rogawski M.A., Löscher W. (2004), “The neurobiology of antiepileptic drugs”, Neture Reviews Neuroscience, 5, 553-564.
  109. Rohsenow D.J. (1983), “Drinking habits and expectancies about alcohol’s effects for self versus others”, Journal of Consulting and Clinical Psychology, 51, 752-756.
  110. Salehi M., Kheirabadi G.R., Maracy M.R., Ranjkesh M. (2011), “Importance of gabapentin dose in treatment of oipoid withdrawal”, Journal of Clinical Psychopharmacology, 31, 593-596.
  111. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. (1993), “Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II”, Addiction, 88, 791-804.
  112. Schacht J.P., Randall P.K., Waid L.R., Baros A.M., Latham P.K., Wright T.M., Myrick H., Anton R.F. (2011), “Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence”, Alcoholism: Clinical and Experimental Research, 35, 2030-2038.
  113. Sheehan D.V., Lecrubier Y., Sheehan K. H., Amorin P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. (1998), “The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10”, Journal of Clinical Psychiatry, 59, suppl. 20, S22-S33.
  114. Singleton E.G., Henningfield J.E., Tiffany S.T. (1994), Alcohol Craving Questionnaire: ACQ-Now: Background and Administration Manual, Baltimore: NIDA Addiction Research Center.
  115. Skinner H.A., Allen B.A. (1982), “Alcohol dependence syndrome: measurement and validation”, Journal of Abnormal Psychology, 91, 199-209.
  116. Skinner H.A., Horn J.L. (1984), Alcohol Dependence Scale (ADS): Users’s Guide, Toronto: Addiction Research, Foundation.
  117. Sobell L.C., Sobell M.B (1992), Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption: Psychosocial and Biochemical Methods, eds: Litten R.Z., Allen J.P. Totowa: Human Press Inc., 41-72.
  118. Sobell L.C., Sobell M.B. (1995), Alcohol Timeline Followback Users’ Manual, Toronto: Addiction Research Foundation.
  119. Sobell L.C., Sobell M.B., Leo G.I., Cancilla A. (1988), “Reliability of a timeline method: assessing normal drinkers’ reports of recent drinking and a comparative evaluation across sevaral populations”, British Journal of Addictions, 83, 393-402.
  120. Sood A., Ebbert J.O., Schroeder D.R., Croghan I.T., Sood R., Vander Weg M.W., Wong G.Y., Hays J.T. (2007), “Gabapentin for smoking cessation: a preliminary investigation of efficacy”, Nicotine and Tobacco Research, 9, 291-298.
  121. Sood A., Ebbert J.O., Wyatt K.D., Croghan I.T., Schroeder D.R., Sood R., Hays J.T. (2010), “Gabapentin for smoking cessation”, Nicotine and Tobacco Research, 12, 300-304.
  122. Stahl S.M. (2014), Psicofarmacologia essenziale. Guida alla prescrizione. Seconda Edizione, Milano: Edi.Ermes.
  123. Stock C.J., Carpenter L., Ying J., Greene T. (2013), “Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment”, Annals of Pharmacotherapy, 47, 961-969.
  124. Stroop J.R. (1935), “Studies of interference in serial verbal reactions”, Journal of Experimental Psychology, 18, 643-662.
  125. Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., Sellers E.M. (1989), “Assessment of alcohol withdrawal: The Revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)”, British Journal of Addiction, 84, 1353-1357.
  126. Urschel H.C. 3rd, Hanselka L.L., Baron M. (2011), “A controlled trial of flumazenil and gabapentin for initial treatment of methylamphetamine dependence”, Journal of Psychopharmacology, 25, 254-262.
  127. Üstün T.B., Kostanjsek N., Chatterji S., Rehm J. (2010), Measuring Health and Disability. Manual for WHO Disability Assessment Schedule, WHODAS 2.0, Geneva: World Health Organization.
  128. Verheul R., Van Den Brink W., Geerlings P. (1999), “A three-pathway psychological model of craving for alcohol”, Alcohol and Alcoholism, 34, 197-222.
  129. Wackernah R.C., Minnick M.J., Clapp P. (2014), “Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment”, Substance Abuse and Rehabilitation, 5, 1-12.
  130. Watson D., Clark L.A., Tellegen A. (1988), “Development and validation of brief measures of positive and negative affect: the PANAS scales”, Journal of Personaliyty and Social Psychology, 54, 1063-1070.
  131. Weathers F.W., Litz B.T. (1994), “Psychometric properties of the Clinician-Administered PTSD Scale, CAPS-1”, PTSD Research Quaterly, 1994, 5, 2-6.
  132. Willenbring M.L., Massey S.H., Gardner M.B. (2009), “Helping patients who drink too much: an evidence-based guide for primary care clinicians”, American Family Physician, 80, 44-50.
  133. Zung W.W.K. (1971), “A rating instrument for anxiety disorders”, Psychosomatics, 12, 371-379.


Caricamento metriche ...